Abstract：
UNASSIGNED: This is a summary of findings from two research studies (known as clinical trials). The studies looked at how well a medicine called relugolix combination therapy worked in women with heavy menstrual bleeding (heavy bleeding during a period) with uterine fibroids (noncancerous or benign growths in the uterus). In this analysis of the studies, researchers looked at how patients self-reported their uterine fibroid symptoms before and after taking relugolix combination therapy. Researchers also looked at how patients self-reported the impact of uterine fibroids on their health-related quality of life before and after taking relugolix combination therapy.
UNASSIGNED: Women took either relugolix combination therapy or placebo (a pill that contains no medicine) by mouth once daily for 24 weeks. Women completed the Uterine Fibroid Symptom and Quality of Life questionnaire (where \"quality of life\" refers to the women\'s health-related quality of life related to uterine fibroids) before, during, and after treatment. The questionnaire let researchers see if the women felt that relugolix combination therapy decreased the burden of uterine fibroid symptoms and improved the women\'s health-related quality of life related to uterine fibroids. More women said that they felt less distress due to their uterine fibroid symptoms and that their health-related quality of life related to uterine fibroids was better after taking relugolix combination therapy compared with women who took placebo.
UNASSIGNED: Relugolix combination therapy may lessen distress associated with uterine fibroid symptoms and improve health-related quality of life related to uterine fibroids.
UNASSIGNED: Women took either relugolix combination therapy or placebo (a pill that contains no medicine) by mouth once daily for 24 weeks. Women completed the Uterine Fibroid Symptom and Quality of Life questionnaire (where \"quality of life\" refers to the women\'s health-related quality of life related to uterine fibroids) before, during, and after treatment. The questionnaire let researchers see if the women felt that relugolix combination therapy decreased the burden of uterine fibroid symptoms and improved the women\'s health-related quality of life related to uterine fibroids. More women said that they felt less distress due to their uterine fibroid symptoms and that their health-related quality of life related to uterine fibroids was better after taking relugolix combination therapy compared with women who took placebo.
UNASSIGNED: Relugolix combination therapy may lessen distress associated with uterine fibroid symptoms and improve health-related quality of life related to uterine fibroids.
摘要：
■这是两项研究（称为临床试验）的发现的摘要。这些研究着眼于称为relugolix联合疗法的药物在患有子宫肌瘤（子宫非癌或良性生长）的月经大量出血（一段时间内大量出血）的女性中的疗效。在这项研究的分析中，研究人员观察了患者在服用relugolix联合治疗前后如何自我报告其子宫肌瘤症状。研究人员还研究了患者在服用relugolix联合治疗前后如何自我报告子宫肌瘤对其健康相关生活质量的影响。
妇女每天口服一次relugolix联合疗法或安慰剂（不含药物的药丸），持续24周。女性在完成子宫肌瘤症状和生活质量问卷（其中“生活质量”是指与子宫肌瘤相关的女性健康相关的生活质量）之前，during,和治疗后。调查问卷让研究人员了解女性是否认为relugolix联合治疗减轻了子宫肌瘤症状的负担，并改善了与子宫肌瘤相关的女性健康相关的生活质量。更多的女性表示，与服用安慰剂的女性相比，服用relugolix联合治疗后，她们因子宫肌瘤症状而感到的痛苦减少，与子宫肌瘤相关的健康相关生活质量更好。
Relugolix联合治疗可以减轻与子宫肌瘤症状相关的痛苦，并改善与子宫肌瘤相关的健康相关生活质量。
妇女每天口服一次relugolix联合疗法或安慰剂（不含药物的药丸），持续24周。女性在完成子宫肌瘤症状和生活质量问卷（其中“生活质量”是指与子宫肌瘤相关的女性健康相关的生活质量）之前，during,和治疗后。调查问卷让研究人员了解女性是否认为relugolix联合治疗减轻了子宫肌瘤症状的负担，并改善了与子宫肌瘤相关的女性健康相关的生活质量。更多的女性表示，与服用安慰剂的女性相比，服用relugolix联合治疗后，她们因子宫肌瘤症状而感到的痛苦减少，与子宫肌瘤相关的健康相关生活质量更好。
Relugolix联合治疗可以减轻与子宫肌瘤症状相关的痛苦，并改善与子宫肌瘤相关的健康相关生活质量。
